Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2021.12.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Steady Quiet Asthma Without Biologics: One-Year Outcomes of Single-Inhaler Triple Therapy for Severe Asthma with Small Airway Dysfunction.
J Clin Med
August 2025
Respiratory Diseases, University of Bari, 70121 Bari, Italy.
Small airway dysfunction (SAD) plays a critical role in the management of severe asthma, particularly in patients at risk of requiring biological therapies (BTs). Short-term studies have shown that switching to single-inhaler triple therapy (SITT) with extrafine beclomethasone-formoterol-glycopyrronium improves outcomes and helps achieve quiet asthma, a state marked by symptom control, no exacerbations or oral steroids, reduced inflammation, and better small airway function. This study investigated whether, over one year, patients could maintain this state as Steady Quiet Asthma (SQA) and whether baseline measures could predict this sustained response.
View Article and Find Full Text PDFImmunological Markers Associated with Skin Manifestations of EGPA.
Int J Mol Sci
August 2025
Department of Clinical and Experimental Medicine, School and Unit of Allergy and Clinical Immunology, "G. Martino" Hospital, University of Messina, 98124 Messina, Italy.
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis with eosinophilic inflammation and variable clinical presentations. Although skin manifestations are frequent, current classification criteria do not include them, which may underestimate their diagnostic value. This prospective observational study aimed to assess systemic and skin involvement as well as eosinophilia, anti-neutrophil cytoplasmic antibody (ANCA), and Anti-nuclear antibodies (ANA) serum levels in 20 EGPA patients followed for one year at the University Hospital of Messina, Italy, before starting Mepolizumab, 300 mg.
View Article and Find Full Text PDFImpact of demographics on mepolizumab effectiveness in severe asthma: One-year REALITI-A subanalysis (12/12 words).
J Allergy Clin Immunol Pract
August 2025
Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Background: There is need for better understanding of the impact of demographic/clinical characteristics on outcomes with mepolizumab in patients with severe asthma.
Objective: Assess mepolizumab outcomes in severe asthma by demographic/clinical characteristics.
Methods: REALITI-A (GSK ID: 204710) was an international, prospective, observational study of adults with severe asthma (eosinophilic phenotype) initiating mepolizumab (100 mg subcutaneous).
One year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study.
Rhinology
July 2025
Unit of Otorhinolaryngology and Head-Neck Surgery.
Background: This study aimed to evaluate the effectiveness of mepolizumab in the treatment of severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as add-on therapy to intranasal corticosteroids (INCS) in a real-life setting over the first year of treatment.
Methodology: We included 50 patients (28 males; mean age: 56.4 years, range 35-77) who received mepolizumab 100 mg every 4 weeks.
Efficacy of tiotropium bromide on spirometric measurements and control of asthma in real life: data from a 1-year clinical follow-up.
J Asthma
September 2025
Department of Chest Diseases, University of Health Sciences Atatürk Sanatoryum Training and Research Hospital, Ankara, Turkey.
Objective: Real-life studies are needed to evaluate the clinical outcomes of add-on tiotropium therapy in patients with asthma. The effects of adding tiotropium bromide to the treatment of asthmatic patients on pulmonary functions and asthma control using real-life data.
Methods: In a retrospective study, spirometric measures and asthma control states were compared before and one year after of tiotropium treatment in asthmatic adults whose disease was not adequately controlled with a combination of inhaled corticosteroids and long-acting β2-agonists.